echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Brooks Automation, the parent company of Jinwei Zhizhi, plans to split into two independent listed companies

    Brooks Automation, the parent company of Jinwei Zhizhi, plans to split into two independent listed companies

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 10, 2021, Brooks Automation, the parent company of Jinwei Zhizhi, announced its plan to split into two independent listed companies to establish a life science company and an automation company with a focus on business and rapid growth
    .


    It is expected that all procedures will be completed before the end of December 2021


    The transaction aims to distribute shares to Brooks shareholders in a tax-efficient manner.
    After the split, it will be established:

    • A dedicated life science company with market-leading sample-based solutions and genomics services
      .


      The company will be renamed before the split is completed to reflect its strategic focus


      Brooks Chairman of the Board of Directors Dave Jarzynka said: "The company split is the result of a comprehensive strategic review conducted by the board of directors and the management team
      .


      Create two independent companies, each with its own focus and mature business model, designed to promote these two The continued development of the business and the creation of value for shareholders


      Brooks' current CEO Steve Schwartz will lead the independent life science company
      .


      The current Brooks CFO Lindon Robertson will serve as CFO


      Dave Jarzynka, the current president of the Semiconductor Solutions Division, will be appointed as the CEO of the new Brooks Automation
      .


      Brooks' current company chief financial officer and chief accounting officer Dave Pietrantoni will be appointed chief financial officer


      Decision-making basis for split strategy

      The life sciences and semiconductor businesses operate in different industry markets and have unique business opportunities and investment requirements
      .


      The Brooks board of directors and management believe that the split will bring substantial benefits to the independent company, including:

      • Strengthen strategic and operational focus
      • Simplify organizational structure and increase flexibility
      • Unique and clear financial situation, with a convincing investment case
      • Consistent performance incentive mechanism
      • A high-quality balance sheet supports organic and inorganic investments

      Split the details

      The transaction plan will distribute shares to Brooks shareholders in a tax-efficient manner
      .


      Brooks' goal is to complete the split by the end of the 2021 calendar year


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.